CLINICAL_TRIALS
trial_result
· 2012-03-27
Clinical Trial Update: Safety and Pharmacology Study of BMS-866949 [Phase 1]
Summary
A Phase 1 safety and pharmacology study of the investigational compound BMS-866949 in major depressive disorder was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Major Depression | Phase 1 | Status: TERMINATED